Searched for
SPARC LTD
Germany to shift beyond student mobility; strengthen research, institutional collaboration in IndiaGermany's academic exchange agency DAAD is changing its focus in India. The agency is moving from just sending students to Germany to build...- Bill Ackman's Pershing Square proposes $64 billion merger deal with Universal Music GroupBill Ackman's Pershing Square proposed a deal on Tuesday to merge Universal Music Group with its investment fund under a plan to revive the...
- Bill Ackman's Pershing Square proposes $64 billion merger deal with Universal Music GroupBill Ackman's Pershing Square has proposed a deal to merge Universal Music Group with its investment fund. The plan aims to revive the musi...
- SPARC enters pact with UCSF and Tiller Therapeutics for early stage oncology assetSun Pharma Advanced Research Company (SPARC) partners with Tiller Therapeutics. SPARC licenses its rights to a promising cancer treatment. ...
- Sun Pharma inks licensing pact with SPARC to commercialise medication in US marketSPARC submitted a new drug application (NDA) to the US Food and Drug Administration (US FDA) for the said product in February 2022.
- SPARC enters licensing pact with Biomodifying for licensing of novel drug targets against cancer“This is an important milestone for SPARC. The licensing of antibodies from Biomodifying will assist us in our endeavour to transition SPAR...
- SPARC seeks shareholders nod to raise up to Rs 1,800 crThe approval is being sought for raising funds for an aggregate consideration of up to Rs 1,800 crore or in equivalent foreign currency, SP...
- Sparc, Sun Pharma move up in lockstep on D-StreetSun Pharma Advanced Research Co (Sparc), the drug discovery business owned by the promoter group of Sun Pharma, is fast emerging.
- USFDA denies approval for SPARC's anti-glaucoma eyedropSun Pharma Advanced Research Company (SPARC) today said the US health regulator has not approved its new drug application for anti-glaucoma...
- SPARC licenses Xelpros to Sun Pharma for US marketSun Pharma Advanced Research Company (SPARC) has licensed out Xelpros, a preservative-free eye drop, to a subsidiary of Sun Pharma for the ...
- BUY SPARC Ltd with a target of Rs 445: Sandeep Wagle'SPARC lTD is a 'BUY' call with a target of Rs 445 and a stop loss of Rs 390'
- Buy SPARC with a target of Rs 228: Mitesh Thacker"SPARC is a 'Buy' call with a target of Rs 228 and a stop loss of Rs 204."
- Buy SPARC with a target Rs 250: Mitesh Thacker"SPARC is a 'Buy' call with a target of Rs 250 and a stop loss of Rs 170."
- Buy SPARC with a target of Rs 195: Mitesh Thacker"SPARC is a 'BUY' call with a target of Rs 195 and a stop loss of Rs 169."
- Buy SPARC with a target of Rs 193: Sandeep Wagle"SPARC Ltd is a 'buy' call with a target of Rs 193 and a stop loss of Rs 167."
- Buy SPARC with a target of Rs 200: Mitesh Thacker"SPARC Ltd is a 'buy' call with a target of Rs 200 and a stop loss of Rs 167."
- Buy SPARC with a target of Rs 190: Mitesh ThackerBuy SPARC with a target of Rs 190 and a stop loss of Rs 168: Mitesh Thacker.
- Buy SPARC with a target of Rs 190: Mitesh ThackerBuy SPARC with a target of Rs 190 and a stoploss of Rs 160: Mitesh Thacker.
- Buy SPARC with target price of Rs 175: Mitesh ThackerBuy SPARC with stop loss of Rs 157 for target of Rs 175.
- Drug discovery firm SPARC Q1 loss widens to Rs 18 croreThe company had posted a net loss of Rs 11.26 crore for the same period of 2011-12 fiscal, SPARC said in a statement.
Load More
